{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001350","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.384696+00:00","generated_at":"2026-05-28T10:54:20.432469+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quoin reports Netherton Syndrome patient achieves near-clear skin after 12 weeks of QRX003 twice-daily","bullets":["M-IASI score improved from 18 to 3; WINRS from 7 to 2; IGA from Moderate to Almost Clear after 12 weeks.","Patient satisfaction scores further improved from 6-week to 12-week mark; no safety concerns observed.","Data follows positive interim results announced Dec 2024; first subject completed full 12-week twice-daily dosing with QRX003.","Quoin is developing QRX003 for Netherton Syndrome, a rare genetic skin disorder with no approved therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001350","json":"https://secwatch.observer/filing/0001104659-25-001350.json","markdown":"https://secwatch.observer/filing/0001104659-25-001350.md","text":"https://secwatch.observer/filing/0001104659-25-001350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925001350/0001104659-25-001350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925001350/tm252105d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T10:54:20.432469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}